Facility 1

Seoul 5030

0 studies enrolling now · 6 studies all time

What they study most

Alzheimer's Disease, Hepatocellular Carcinoma (HCC), Insomnia Disorder, Partial-Onset or Primary Generalized Tonic-Clonic Seizures, Thyroid Cancer

Studies at this site

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) — Completed
• Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures — Completed
• A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma — Completed
• A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile — Completed
• A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease — Stopped early
• Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2) — Completed